BridgeBio Oncology Therapeutics Inc. (BBOT) vs Larimar Therapeutics, Inc. (LRMR)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and Larimar Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.62HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
LRMR
Larimar Therapeutics, Inc.
$2.84HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — BBOT vs LRMR
growth of $100 · dividends reinvested · last 3yBBOT -64.7% (-29.3%/yr)LRMR -53.9% (-22.7%/yr)LRMR compounded faster over this window
BBOT LRMR
BBOT vs LRMR: by the numbers
- •LRMR is the larger company ($295M vs $290M market cap).
Metrics side by side
Valuation
| Metric | BBOT | LRMR |
|---|---|---|
| P/B ratio | 0.90 | 2.32 |
Profitability
| Metric | BBOT | LRMR |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -56.36% | -135.50% |
| ROIC | -61.10% | -136.49% |
Growth (annualized)
| Metric | BBOT | LRMR |
|---|---|---|
| Total return CAGR (5Y) | N/A | -23.91% |
Go deeper
Dig into the metrics
BridgeBio Oncology Therapeutics ROELarimar Therapeutics ROEBridgeBio Oncology Therapeutics operating marginLarimar Therapeutics operating marginBridgeBio Oncology Therapeutics revenue growthLarimar Therapeutics revenue growthBridgeBio Oncology Therapeutics free cash flowLarimar Therapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.